Clinical Trials
16 trialsNCT03583528 2026-05-12
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06045260 2024-08-13
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT06523582 2024-07-26
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Recruiting
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT04788927 2023-04-07
PPGL-Pred
Rigshospitalet, Denmark
Not yet recruiting
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
NCT03923257 2021-06-08
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Phase 1/2 Withdrawn
NCT04017104 2021-01-26
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
Unknown
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT04029428 2020-04-01
POLNETS_PRRT
University of Warmia and Mazury
Phase 2 Unknown
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT01941849 2015-12-21
VIBRaNT
University College, London
Phase 1 Withdrawn